Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

Sept. 10, 2020 12:00 UTC

 

 
 

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences:

  • H.C. Wainwright 22nd Annual Global Investment Conference
    Presentation Date: Monday, September 14, 2020
    Time: 3:30 p.m. ET
  • 2020 Cantor Global Virtual Healthcare Conference
    Presentation Date: Wednesday, September 16, 2020 (Fireside Chat)
    Time: 2:40 p.m. ET

A live webcast of the presentations will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com. After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Contacts

Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com

 
 

Source: Aldeyra Therapeutics, Inc.

Back to news